Literature DB >> 18314859

Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression.

Rhee-Hun Kang1, Myoung-Jin Choi, Jong-Woo Paik, Sang-Woo Hahn, Min-Soo Lee.   

Abstract

The 5-HTR2A gene is a candidate gene for influencing the clinical response to treatment with antidepressants. The purpose of this study was to determine the relationship between the -1438A/G polymorphism of the 5-HTR2A gene and the response to mirtazapine in a Korean population with major depressive disorder. Mirtazapine was administered for eight weeks to the 101 patients who completed the study, during which we evaluated the clinical outcome using repeated-measures ANCOVA. A main effect of genotype or an effect of genotype-time interactions on the decrease in HAMD score during the eight-week follow-up was not found, which suggests that the 5-HTR2A -1438A/G polymorphism does not affect the clinical outcome to mirtazapine administration. However, significant effects of genotype and allele carriers on the decrease in the sleep score over the eight weeks were found (genotype: F = 4.093, p = 0.017; allele: F = 4.371, p = 0.037), whereas no effect of genotype-time interactions on the decrease in the HAMD score over the eight-week follow-up was found. These observations suggest that the -1438A/G polymorphism on the sleep improvement at each time period revealed significant differences in the sleep scores after two weeks of mirtazapine administration. The sleep scores were lower for carriers of the A+ allele than of the A- allele after two weeks of mirtazapine administration (p = 0.041), which means that the -1438GG genotype is associated with less improvement in sleep, and suggests that the effect of mirtazapine on improving the sleep quality differs with the 5-HTR2A -1438A/G polymorphism within two weeks of mirtazapine treatment. In conclusion, although the -1438A/G polymorphism affects the sleep improvement resulting from the administration of mirtazapine to Korean patients with major depressive disorder, our results do not support the hypothesis that this polymorphism of the 5-HTR2A gene is involved in the therapeutic response to mirtazapine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18314859     DOI: 10.2190/PM.37.3.h

Source DB:  PubMed          Journal:  Int J Psychiatry Med        ISSN: 0091-2174            Impact factor:   1.210


  10 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 2.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

Review 3.  Genetic endophenotypes for insomnia of major depressive disorder and treatment-induced insomnia.

Authors:  Ibrahim Mohammed Badamasi; Munn Sann Lye; Normala Ibrahim; Johnson Stanslas
Journal:  J Neural Transm (Vienna)       Date:  2019-05-18       Impact factor: 3.575

4.  Race, genetic ancestry and response to antidepressant treatment for major depression.

Authors:  Eleanor Murphy; Liping Hou; Brion S Maher; Girma Woldehawariat; Layla Kassem; Nirmala Akula; Gonzalo Laje; Francis J McMahon
Journal:  Neuropsychopharmacology       Date:  2013-07-05       Impact factor: 7.853

Review 5.  Blood-based biomarkers predicting response to antidepressants.

Authors:  Yasmin Busch; Andreas Menke
Journal:  J Neural Transm (Vienna)       Date:  2018-01-27       Impact factor: 3.575

Review 6.  Human biomarkers of rapid antidepressant effects.

Authors:  Carlos A Zarate; Daniel C Mathews; Maura L Furey
Journal:  Biol Psychiatry       Date:  2013-01-29       Impact factor: 13.382

7.  Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion.

Authors:  Janet S Carpenter; Menggang Yu; Jingwei Wu; Diane Von Ah; Jennifer Milata; Julie L Otte; Shelley Johns; Bryan Schneider; Anna Maria Storniolo; Ronald Salomon; Zeuresenay Desta; Donghua Cao; Yan Jin; Santosh Philips; Todd C Skaar
Journal:  Menopause       Date:  2009 Jul-Aug       Impact factor: 2.953

Review 8.  Does effective management of sleep disorders reduce depressive symptoms and the risk of depression?

Authors:  Dieter Riemann
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 9.  From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Authors:  Chiara Fabbri; Stefano Porcelli; Alessandro Serretti
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

10.  Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis.

Authors:  Yuan-Sheng Wan; Xue-Jia Zhai; You-Sheng Ai; Li-Bo Zhao; Hong-Ai Tan
Journal:  Pharmacogenomics J       Date:  2020-10-23       Impact factor: 3.550

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.